OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


New Genetic Mutation Increases Risk of Ovarian Cancer

Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer.  This major finding was published online in the journal Nature Genetics on August 7th.

Much like the BRCA1 and BRCA2 mutations, which were discovered in the 1990s and which also increase a woman’s risk for ovarian cancer, those who carry this newly discovered mutation, called RAD51D, have a far greater chance—1 in 11—of developing the disease.  Unlike the BRCA mutations, it doesn’t appear that the RAD51D mutation increases risk for breast cancer.

No commercial test for RAD51D is currently available, but researchers hope that one will be in the next few years.  A test for the RAD15D mutation could allow women who have a family history of ovarian cancer to consider preventative strategies to reduce their risk of developing the disease.

Furthermore, researchers are optimistic that drugs to specifically target this mutation will be available.  In early studies, PARP inhibitors, which are currently being investigated in BRCA-deficient ovarian cancers, have shown promise in treating RAD51D related ovarian cancer as well.

Click here for more information.